logo-loader
Pressure BioSciences Inc.

Pressure BioSciences shares jump after life sciences company sets up Center of Excellence at NYU lab

Dr. Christine Vogel’s lab, which focuses on the study of proteins, will enjoy free use of Pressure BioSciences’s primary instrument system, the Barocycler 2320EXTREME, until the close of 2020

pair of test tubes
Dr Vogel, an associate professor at NYU, is an expert in the study of proteins

Pressure BioSciences Inc (OTCMKTS:PBIO) on Wednesday announced the establishment of a Center of Excellence at Dr. Christine Vogel’s laboratory at New York University’s Center for Genomics and Systems Biology.

As part of this new distinction, Dr Vogel’s lab will enjoy free use of Pressure BioSciences’s primary instrument system, the Barocycler 2320EXTREME, known as the ‘2320EXT’ until the close of 2020.

Under the new collaboration, Dr. Vogel and her colleagues, as well as visitors to her lab, will use the company’s patented pressure cycling technology platform as an aid in the development and confirmation of protocols for tissue-based protein studies that may go on to be used in clinical trials.

READ: Tests show Pressure BioSciences' Ultra Shear Technology effective for processing CBD oil

Investors applauded the news, sending Pressure BioSciences shares up 6.25% to $3.40 in afternoon trade on Wednesday.

Dr Vogel, an associate professor at NYU, is an expert in the study of proteins and their relationship to cancer and other diseases. Dr Vogel’s lab uses the latest equipment and methods to examine the properties of proteins and their association with diseases.

“The 2320 EXT is currently used by research scientists worldwide for the safe, rapid and reproducible lysis of cells and tissues, to release proteins and other important biomolecules (DNA, RNA and lipids) for analysis,” said Roxana McCloskey, Pressure BioSciences’s global director of sales and marketing, in a statement.

READ: Pressure BioSciences' PCT platform could play key role in improving cancer diagnosis

“Such analyses are a critical step in the discovery and development of diagnostic, prognostic and predictive clinical tests used to identify risk, disease presence or disease progression, and to guide treatment in many diseases such as cancer,” McCloskey added.

Dr Vogel is enthusiastic about the introduction of the ‘2320EXT’ to her lab.

“My laboratory uses the most advanced technologies available to investigate the regulation of proteins in different systems in response to environmental stress,” Vogel said in a statement. “We continually look for powerful, cutting-edge tools to help us reach the highest level of quality possible in our research.”

Richard Schumacher, Pressure Bio’s CEO, is similiarly bullish on the partnership and calls Vogel "a thought leader" in the study of proteins.

"To have a scientist of the caliber of Professor Vogel and an institute like the Center for Genomics and Systems Biology, and a university like NYU agree to be recognized as a Center of Excellence speaks volumes of what they think about PBI and our pressure technology platforms," Schumacher wrote in an email to Proactive Investors.

The NYU Center for Genomics and Systems Biology is considered a “hub of science” in New York City. Its facilities include “loft laboratories” where scientists gather to investigate genomics and systems biology.

Thanks to the new partnership, the Vogel laboratory will be open to scientists for workshops and seminars on the use of ‘2320EXT’ in the identification of proteins that might be involved in disease.

Headquartered in South Easton, Massachusetts, Pressure BioSciences provides high pressure-based scientific instruments for biomarker discovery, drug design and development, food science, forensics and counter-bioterror applications.

Contact Ellen Kelleher at [email protected]

-- This story is updated to reflect latest share price movement --

 

Quick facts: Pressure BioSciences Inc.

Price: $3.24

Market: OTCQB
Market Cap: $6.28 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Pressure BioSciences Inc. named herein, including the promotion by the Company of Pressure BioSciences Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Pressure BioSciences CEO sees potential opportunity to enter...

Pressure BioSciences Inc (OTCMKTS:PBIO) CEO Ric Schumacher tells Proactive the medical device company's signature Pressure Cycling Technology (PCT) platform has been highlighted by scientists in China and Australia, which Schumacher says could eventually propel the company into the clinical...

1 week, 4 days ago

3 min read